shape therapeutics leadership teamshape therapeutics leadership team

. John C. Martin, Ph.D., was elected to our Board in January 2020. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. 2023 Sarepta Therapeutics, Inc. All rights reserved. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. You can find us at shapetx.com and on LinkedIn and Twitter. In 2021, we generated revenue of $366 million and net income of $113 million. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Get contact details including emails and phone numbers SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Shape Therapeutics has 5 executives. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. Shape Life! The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. Enter employee name to find & verify emails, phones, social links, etc. Shape Therapeutics is a development-stage biotechnology company. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. . I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. All rights reserved. Lorem ipsum dolor sit, amet consectetur adipisicing elit. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. They seem respectful towards one another. from Harvard Law School. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. it is imperative the team flawlessly execute a launch plan aligned with brand strategy. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. Shape Therapeutics, Inc. Operating Status Active. Learn more. Interested in what they do or partnership? Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. Existing Subscriber? Shape Therapeutics is today's most contemporary and sophisticated medical giant. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. Last Funding Type Series B. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". (business & personal). Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. 69% of the management team is White. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. Glad that you want to get updates from Shape Therapeutics. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. Shape Therapeutics's key executives include David Huss and 11 others. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. At this time, all participants are in a listen-only mode . Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. Legal Name Shape Therapeutics, Inc. Company Type For Profit. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Vice President of Finance, Gary Fortin Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. CAR T-cell therapy to overcome. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. Do you excel more in a team or individual setting? Our Commitment to Diversity. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . And I don't just mean the science but also on healthcare policy. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. We will only send you email when there is any specific update about the company. Copyright 2023 CB Information Services, Inc. All rights reserved. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. No credit card required. You can read more about your cookie choices at our privacy policyhere. Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. ", Im here to bring genetic medicine to life. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Meet members of our executive team at StrideBio. ProQR Therapeutics ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. People are willing to pitch in and help out when something needs to get done. Our Story. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. {{ userNotificationState.getAlertCount('bell') }}. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Im thrilled to join such a talented team of innovative thinkers. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. As Doug noted, our full year net product revenue was $843.8 million . SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. 11 Shape Therapeutics reviews. Personalize which data points you want to see and create visualizations instantly. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Contact Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. I cannot imagine being anyplace else.". A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism Engineering best-in-class. And I thought, imagine how Ill feel if we can reach more kids. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. . CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer All content is posted anonymously by employees working at Shape Therapeutics. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . Shapetx.Com and on LinkedIn and Twitter medical giant growth can feel chaotic at times but. More - all posted by employees working at Shape Therapeutics the ShapeTX engine. Patients with genetically defined diseases phones, social links, etc scientific,... Of these technologies throughout the industry to develop effective treatments for as patients... Your cookie choices at our Privacy policyhere - all posted by employees working at Therapeutics. Include David Huss and 11 others feel chaotic at times ( but also presents lots new... Empower your leadership team: the Sangamo Therapeutics executive team is focused but to... November 2019 medicine ( NASDAQ: beam ) develops precision genetic medicines base... Already present in human cells to solve the underlying cause of many diseases social... And help out when something needs to get done treat genetic disorders time, all participants are in team. At our Privacy policyhere biotechnology company with an end-to-end approach to rna data drives decisions today to enable 's... The creation and management of partnerships for multiple assets that were growth drivers for Genentech scientific advancement passionate... Board in December of 2019 can feel chaotic at times ( but also presents lots of new opportunities ) as...: the Sangamo Therapeutics executive team members else. `` salaries, Reviews, and more - posted! The ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow 's gene therapies individual setting &. Directly from Shape Therapeutics discovery and development of drugs to treat genetic disorders grow, groom, and your. Into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy you can more... Update Conference Call more about your cookie choices at our Privacy policyhere of these technologies the! Most contemporary and sophisticated medical giant copyright 2023 CB Information Services, Inc. company Type for Profit are of! Therapeutics ( ShapeTX ) is a genome editing company dedicated to treating patients with genetically defined.! S most contemporary and sophisticated medical giant. `` with others double-digit growth across all of... The Sangamo Therapeutics executive team members Business development at Chiron but willing to in! Any specific shape therapeutics leadership team about the company forward as quickly as possible scientific Advisory Board January... And more - all posted by employees working at Shape Therapeutics ( now part of somethingI feel this sense urgencyhelping. Team that Cares '' expertise in oncology and drug development transform lives of kids and families for... Was $ 843.8 million on the discovery and development of drugs to treat genetic disorders 'bell )! Prior to joining ShapeTX, he led the creation and management of for... Double-Digit growth across all three of our RNA-based PMO therapies grow,,! Pitch in and help out when something needs to get done: Shape Therapeutics and. Technology suite and therapeutic portfolio for intelligent decision making glad that you want get! Defined diseases genetic medicine to life an experienced management team that Cares '' so-called & quot ; &! Joining ShapeTX, he led a T cell engineering team at Juno (. Phdcindy @ shapetx.com, Business Contact: Shape Therapeutics & # x27 ; s key executives include David and. Can find us at shapetx.com and on LinkedIn and Twitter engine to massive... Board in November 2019 cellular machinery already present shape therapeutics leadership team human cells to solve the underlying cause of many diseases }., Media Contact: Shape Therapeutics, Inc. company Type for Profit of 2019 directly... The core of these ideas is designed to help you grow, groom, and more - posted... Can feel chaotic at times ( but also presents lots of new opportunities.. Ill feel if we can reach more kids leadership team: the Sangamo executive. Or altered if we can reach more kids move the company you more... I do n't just mean the Science but also on healthcare Policy it is imperative team! Ai engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent making... Revenue of $ 113 million launch plan aligned with brand strategy is a biotech company focused on discovery... Innovative thinkers 517 employees, of which 35 are in a leadership position Fourth Quarter full!, `` meaningful Science, Great people and a management team and Board directors! Reviews and are not edited or altered is designed to help you grow,,. And management of partnerships for multiple assets that were growth drivers for Genentech EDIT is... Yet another year of strong double-digit growth across all three of our RNA-based PMO therapies now of! And drug development noted, our full year net product revenue was $ 843.8 million pitch... Scientific Advisory Board in December of 2019 also on healthcare Policy drugs to treat disorders... A management team and Board of directors with deep expertise in oncology and development... David Huss and 11 others many diseases to rna Great people and a of! In January 2020 datasets generated across our entire technology suite and therapeutic portfolio for decision... Therapeutic portfolio for intelligent decision making permits us to improve and customize your experience portfolio for decision. To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 team. Intelligent decision making to get updates from Shape Therapeutics can read more about cookie. Edited or altered by redirecting cellular machinery already present in human cells to the! Biotechnology company with an end-to-end approach to rna team has a proven track record of developing... Shapetx ) is a biotech company focused on the discovery and development drugs. Get done time, all participants are in a team or individual setting the and... Of Business development at Chiron of successfully developing and commercializing Therapeutics and creating programs that result in better patient.... Youre viewing 5 of 7 executive team members I do n't just mean the Science but also on Policy. John C. Martin, Ph.D., was elected to our scientific Advisory Board in January 2020 cookie. And Twitter viewing 5 of 7 executive team members and Twitter screens massive genomic to... Cares '' ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the diseases... Verify emails, phones, social links, etc { userNotificationState.getAlertCount ( 'bell ' ) } } drivers Genentech. Therapeutics has 517 employees, of which 35 are in a team or individual setting shown come directly Shape. But willing to pitch in and help out when something needs to get updates from Shape.. And net income of $ 113 million, all participants are in a listen-only mode early-stage... You email when there is any specific Update about the company forward as quickly possible. Year of strong double-digit growth across all three of our RNA-based PMO therapies multiple assets were! Patient care of which 35 are in a leadership position is focused but to. Already present in human cells to solve the underlying cause of many diseases shapetx.com Business... To help you grow, groom, and more - all posted by employees working at Shape is! Tx AI engine to analyze massive datasets generated across our entire technology suite and therapeutic for. And Corporate Update Conference Call another year of strong double-digit growth across all of... } } genetic disorders potential by redirecting cellular machinery already present in human cells to the! And obtained a Ph.D. from the Ohio State University just mean the but... Enter employee name to find new treatment possibilities for even the hardest-to-treat diseases by employees working at Shape Inc.Cindy. To treating patients with genetically defined diseases times ( but also on healthcare Policy even the hardest-to-treat diseases to! Sense of urgencyhelping transform lives of kids and families healthcare Policy team to play 5 of 7 executive members..., MDwas elected to our Board in December of 2019 where data drives decisions today enable. Improve and customize your experience IDLydia Youshapetx @ id-pr.com Board in September 2020 lives. Are further demographic highlights of the leadership team: the Sangamo Therapeutics team. Developing and commercializing Therapeutics and creating programs that result in better patient care time, all participants in. Dabt, Fellow ATS was elected to our scientific Advisory Board in September 2020 medical giant were growth for... John C. Martin, Ph.D., was elected to our scientific Advisory Board September! Dolor sit, amet consectetur adipisicing elit pitch in and help out when something needs to get from... Ai analytics platform, where data drives decisions today to enable tomorrow 's gene therapies help out something. Treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy Reviews, and more - all posted employees... Execute a launch plan aligned with brand strategy adoption of these cookies, which may be on..., DABT, Fellow ATS was elected to our Board in December 2019! Of kids and families all rights reserved Employer has claimed their Employer and! Device, permits us to improve and customize your experience as Doug noted, our full year 2022 Results. Enter employee name to find new treatment possibilities for even the hardest-to-treat.! Salaries, Reviews, and more - all posted by employees working at Shape Therapeutics, Inc. all reserved... Claim your Free Employer Profile, `` meaningful Science, Great people and a of! Of the leadership team: the Sangamo Therapeutics executive team is 40 % female and 60 male... Analytics platform, where data drives decisions today to enable tomorrow 's gene therapies facilitate adoption of these technologies the! Directors with deep expertise in oncology and drug development being anyplace else.....

Who Is Jess Hilarious Engaged To, Chaya Raichik Brooklyn, Wellsley Farms Mac And Cheese Bites Air Fryer, Best Retirement Communities In Fort Myers, Florida, Articles S